Swedish Orphan Biovitrum AB (publ) (FRA:B6E)
Germany · Delayed Price · Currency is EUR 31.84
+0.50 (1.60%)
Last updated: Jan 30, 2026, 9:30 AM CET
FRA:B6E Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 27,852 | 26,027 | 22,123 | 18,790 | 15,529 | 15,261 | |
Revenue Growth (YoY) | 9.50% | 17.65% | 17.74% | 21.00% | 1.76% | 7.11% |
Cost of Revenue | 6,084 | 5,717 | 4,963 | 4,413 | 3,484 | 3,225 |
Gross Profit | 21,768 | 20,310 | 17,160 | 14,377 | 12,045 | 12,036 |
Selling, General & Admin | 11,233 | 10,967 | 9,773 | 7,637 | 6,294 | 5,981 |
Research & Development | 3,351 | 3,529 | 2,743 | 2,252 | 1,987 | 1,594 |
Other Operating Expenses | 49 | -9 | -9 | -32 | -30 | -2 |
Operating Expenses | 14,633 | 14,487 | 12,507 | 9,857 | 8,251 | 7,573 |
Operating Income | 7,135 | 5,823 | 4,653 | 4,520 | 3,794 | 4,463 |
Interest Expense | -891 | -1,239 | -1,111 | -458 | -419 | -454 |
Interest & Investment Income | 70 | 70 | 27 | 5 | - | 1 |
Currency Exchange Gain (Loss) | 9 | 9 | -91 | -44 | 18 | -157 |
Other Non Operating Income (Expenses) | -59 | -59 | -49 | -27 | -35 | -33 |
EBT Excluding Unusual Items | 6,264 | 4,604 | 3,429 | 3,996 | 3,358 | 3,820 |
Merger & Restructuring Charges | -477 | -210 | -23 | -363 | - | - |
Gain (Loss) on Sale of Assets | -2 | -2 | -1 | - | -56 | -2 |
Asset Writedown | -6,612 | 15 | -65 | - | -7 | - |
Other Unusual Items | 127 | - | -385 | -312 | - | 399 |
Pretax Income | -700 | 4,407 | 2,955 | 3,321 | 3,295 | 4,217 |
Income Tax Expense | -705 | 528 | 546 | 683 | 616 | 972 |
Earnings From Continuing Operations | 5 | 3,879 | 2,409 | 2,638 | 2,679 | 3,245 |
Minority Interest in Earnings | 8 | 6 | - | - | - | - |
Net Income | 13 | 3,885 | 2,409 | 2,638 | 2,679 | 3,245 |
Net Income to Common | 13 | 3,885 | 2,409 | 2,638 | 2,679 | 3,245 |
Net Income Growth | -99.63% | 61.27% | -8.68% | -1.53% | -17.44% | -1.79% |
Shares Outstanding (Basic) | 344 | 342 | 323 | 296 | 295 | 295 |
Shares Outstanding (Diluted) | 345 | 346 | 326 | 298 | 297 | 298 |
Shares Change (YoY) | -1.02% | 6.01% | 9.22% | 0.56% | -0.28% | 1.06% |
EPS (Basic) | 0.04 | 11.37 | 7.47 | 8.92 | 9.08 | 11.01 |
EPS (Diluted) | 0.04 | 11.24 | 7.39 | 8.84 | 9.03 | 10.90 |
EPS Growth | -99.63% | 52.10% | -16.39% | -2.11% | -17.16% | -2.85% |
Free Cash Flow | 7,334 | 7,218 | 3,597 | 4,504 | 5,423 | 4,885 |
Free Cash Flow Per Share | 21.27 | 20.89 | 11.04 | 15.09 | 18.27 | 16.41 |
Gross Margin | 78.16% | 78.03% | 77.57% | 76.51% | 77.56% | 78.87% |
Operating Margin | 25.62% | 22.37% | 21.03% | 24.05% | 24.43% | 29.24% |
Profit Margin | 0.05% | 14.93% | 10.89% | 14.04% | 17.25% | 21.26% |
Free Cash Flow Margin | 26.33% | 27.73% | 16.26% | 23.97% | 34.92% | 32.01% |
EBITDA | 10,577 | 9,282 | 7,537 | 6,593 | 5,604 | 6,319 |
EBITDA Margin | 37.98% | 35.66% | 34.07% | 35.09% | 36.09% | 41.41% |
D&A For EBITDA | 3,442 | 3,459 | 2,884 | 2,073 | 1,810 | 1,856 |
EBIT | 7,135 | 5,823 | 4,653 | 4,520 | 3,794 | 4,463 |
EBIT Margin | 25.62% | 22.37% | 21.03% | 24.05% | 24.43% | 29.24% |
Effective Tax Rate | - | 11.98% | 18.48% | 20.57% | 18.70% | 23.05% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.